CSIMarket Company Name, Ticker, Industry, else..
 
Immix Biopharma Inc   (NASDAQ: IMMX)
Other Ticker:  
 
 
Price: $1.8300 $-0.02 -1.081%
Day's High: $1.88 Week Perf: 0.55 %
Day's Low: $ 1.75 30 Day Perf: 12.27 %
Volume (M): 12 52 Wk High: $ 3.23
Volume (M$): $ 23 52 Wk Avg: $2.01
Open: $1.88 52 Wk Low: $1.26



 Market Capitalization (Millions $) 54
 Shares Outstanding (Millions) 29
 Employees 19
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Immix Biopharma Inc
Immix Biopharma Inc is a biotechnology company focused on developing novel cancer immunotherapies. Their main goal is to harness the power of the immune system to effectively eliminate cancer cells. The company is engaged in the research and development of a proprietary platform technology known as the Immune-Directed Enzyme Prodrug Therapy (Immune-Directed EPT). This technology enables the targeted delivery of therapeutic enzymes to cancer cells, which then activates prodrugs to induce an immune response against the tumor. Immix Biopharma aims to develop innovative and personalized treatments that have the potential to improve patient outcomes in various types of cancers.


   Company Address: 11400 West Olympic Blvd. Los Angeles 90064 CA
   Company Phone Number: 651-8041   Stock Exchange / Ticker: NASDAQ IMMX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.8%    
KPTI   -21.01%    
NRIX   -8.22%    
RYTM        0.13% 
SUPN        0.03% 
YMAB   -1.4%    
• View Complete Report
   



Immix Biopharma Inc

Immix Biopharma Inc's Operating Deficit Grows in Fourth Quarter of 2023

Immix Biopharma Inc, a clinical-stage company specializing in the development of cell therapies for autoimmune diseases, has recently announced its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-5.375852 million during this period, and while the respective revenue has not been disclosed, it is important to analyze the corporate efforts from the previous year for a better understanding of the current scenario.
In the fourth quarter of 2022, Immix Biopharma Inc recorded an operating deficit of $-3.794578 million, indicating a significant increase in the deficit in the most recent fiscal period. Additionally, the company reported a shortfall of $-5.155 million, which expanded from $-3.800 million in the corresponding quarter a year ago.
Clinical Study

Trailblazing Cell Therapies in Autoimmune Diseases: Immix Biopharma's Progress Update and Future Perspectives

Published Wed, Feb 21 2024 2:31 PM UTC

In the ever-evolving field of biopharmaceuticals, Immix Biopharma, a clinical-stage company, has been making remarkable strides in the development of cell therapies for autoimmune diseases. This article presents a comprehensive review of Immix Biopharma s 12-month progress update, highlighting key achievements and assessing their impact on the company s growth and future pr...
Announcement

Charting New Courses: Immix Biopharma's Proposed Public Offering of Common Stock.

Published Mon, Feb 5 2024 8:20 PM UTC

In a significant announcement made recently, Immix Biopharma Inc., a clinical-stage biopharmaceutical company pioneering in cell therapies for autoimmune disease, has declared its intention of floating an underwritten public offering of its common stock. This leading-edge move opens up a new chapter in the growth of the company, mapping out an exciting prospective pathway fo...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com